Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Antibody Combo Expands Response to Checkpoint Inhibitor in Mice

Antibody Combo Expands Response to Checkpoint Inhibitor in Mice

May 24, 2018News, Recombinant Antibody R&D, Therapeutic Antibody R&Dantibody discovery, checkpoints, monoclonal antibody, monoclonal antibody drug, therapeutic antibodybiorab

Checkpoint inhibitor drugs, those that pull the brakes off the immune system, can cause dramatic improvements in cancer patients, but the benefits are far from universal. In the case of atezolizumab (Tecentriq),Read More…

Breakthrough Enables Screening Millions of Human Antibodies for New Drug Discovery

May 24, 2018News, Recombinant Antibody R&D, Therapeutic Antibody R&Dantibody discovery, antibody screening, monoclonal antibody drug, therapeutic antibodybiorab

“A new article outlines a pioneering method of screening a person’s diverse set of antibodies for rapid therapeutic discovery. Antibody proteins are an important part of the human immune system that specificallyRead More…

Development History of Keytruda (Pembrolizumab)

May 24, 2018News, Recombinant Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

Keytruda (pembrolizumab) is a drug developed by Merck (or MSD outside of the U.S. and Canada). It has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of aRead More…

European Commission Approves XGEVA® (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma

April 26, 2018News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

At the beginning of this month, European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events (SRE) in adults with advanced malignancies involving bone, basedRead More…

autoimmune-diseases

MGH team engineers anti-inflammatory antibodies that may treat autoimmune disease

January 5, 2018Antibody Engineering R&D, Newsantibody discoverybiorab

“A team of investigators has found a way to engineer antibodies within an organism, converting autoantibodies that attack ‘self’ tissues into anti-inflammatory antibodies in animal models of two autoimmune diseases.” A teamRead More…

new antibody to fight bone metastatis

A new weapon against bone metastasis? Princeton lab develops antibody to fight cancer

January 5, 2018News, Therapeutic Antibody R&Dtherapeutic antibodybiorab

“During the past decade preclinical studies have defined many of the mechanisms used by tumours to hijack the skeleton and promote bone metastasis. This has led to the development and widespread clinicalRead More…

FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors

January 4, 2018News, Recombinant Antibody R&D, Therapeutic Antibody R&Dmonoclonal antibody drugbiorab

“Emicizumab (trade name Hemlibra, emicizumab–kxwh, ACE910, RO5534262) is a bispecific IgG4 mAb targeting Factors IXa and X. On November 16, 2017, the drug (emicizumab–kxwh) was approved by Food and Drug Administration (FDA) approved to preventRead More…

Posts navigation

  • « Previous
  • 1
  • 2
  • 3
  • 4

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • Scientists Reviewed the Advances, Challenges and Countermeasures in Immunotherapy of Gastrointestinal Tumors
  • Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations
  • The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients
  • Scientists Discovered the Key Molecule Triggering Cancer Metastasis
  • Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Designed and Developed by templatesnext